Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 110
- Registration Number
- NCT02611687
- Locations
- 🇫🇷
Hôpital Femme-Mère-Enfant, Bron, France
🇳🇱Polikliniek Heemstede Neurologist-Somnologist, Heemstede, Netherlands
🇮🇹Università di Bologna, Bologna, Italy
First-time-in-man, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 48
- Registration Number
- NCT01965301
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 53
- Registration Number
- NCT01948011
- Locations
- 🇫🇷
Eurofins Optimed, Gières, France
Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-02-27
- Last Posted Date
- 2016-08-31
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 103
- Registration Number
- NCT01800045
- Locations
- ðŸ‡ðŸ‡º
State Health Center, Budapest, Hungary
Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 51
- Registration Number
- NCT01789398
- Locations
- 🇫🇷
CHU Montpellier, Montpellier, France
Efficacy and Safety of BP1.4979 in Smoking Cessation
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 219
- Registration Number
- NCT01785147
- Locations
- 🇫🇷
Hôpital Paul Brousse, Villejuif, Ile de France, France
Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 180
- Registration Number
- NCT01638403
- Locations
- 🇫🇷
Evelyne DESCHAMPS DE PAILLETTE, Paris, France
Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2012-06-15
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 110
- Registration Number
- NCT01620554
- Locations
- 🇫🇷
CHU de Grenoble, Grenoble, France
Pharmacokinetics of BF2.649 in Renal Impairment
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 25
- Registration Number
- NCT01619033
- Locations
- 🇫🇷
EUROFINS OPTIMED Lyon, Lyon, France
Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 102
- Registration Number
- NCT01399606
- Locations
- 🇫🇷
CHU Montpellier, Montpellier, France
© Copyright 2024. All Rights Reserved by MedPath